HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

New Products: Once-a-month Actonel option approved

Once monthly dose of Actonel has been approved to treating and preventing postmenopausal osteoporosis.

The Agency okayed the new dosage on the basis of a study of 642 women that compared 150 mg of Actonel monthly to 5 mg daily of the tablet. The study showed similar increases for both groups in lumbar spine bone mineral density and at other sites from baseline at 1 year. Produced by Procter and Gamble Pharmaceuticals, the drug is marketed by Sanofi-Aventis U.S. For more information on Actonel, visit the Web site at http://www.actonel.com/.